Arkolith/Insider Trading/ZNTL/Form 4

Paul Andrea

Chief Legal OfficerZentalis Pharmaceuticals, Inc. (ZNTL) · full profile →Form 4 · filed Feb 5, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$38K
Net Open-Market Flow
-$38K
Transactions
4
2 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 2, 2024Sell(S)3K$11.54$38K150K
Feb 1, 2024Grant(A)113K—$0153K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 1, 2024Grant(A)90K—$090K
Feb 1, 2024Grant(A)113K—$0113K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001725160-24-000032) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML